Increased regulatory requirements, insufficient innovation and intense competition from smaller manufacturers and generics all point to an unsustainable business model for big pharma. Payments for best-selling drugs in the US continue to rise and are becoming cost-prohibitive for those living on the economic margins and insurance providers are increasingly demanding evidence of the link between a prescription drug’s price and patient outcomes. Helping pharmaceutical companies find ways to bend the cost curve to improve the access the affordability of their drugs and develop more sustainable business models is the work of ICCR members engaging top U.S. pharma companies.

Featured ICCR Initiative

  1. Call on pharmaceutical companies to educate and inform patients about their coverage options through health insurance exchanges and expanded Medicaid.
  2. Call on pharmaceutical companies to address any gaps in prescription drug coverage, via their prescription assistance programs or other means.
  3. Ask pharmaceutical companies to demonstrate cost effective practices and development of new business models that will increase access to health. 

Featured Resources

PharmaFutures: Global Pathways to Value. Report examining the changing societal expectations affecting pharmaceutical companies.

Bitter Pill: Why Medical Bills are Killing US.  How outrageous pricing and egregious profits are destroying our health care system. 

 Five Things to Know About How Drug Prices Are Set

Why the U.S. Pays More Than Other Countries for Drugs (Dec. 1)

For Prescription Drug Makers, Price Increases Drive Revenue (Oct. 5)

New Push Ties Cost of Drugs to How Well They Work (May 26)

Pharmaceutical Companies Buy Rivals’ Drugs, Then Jack Up the Prices (April 26)

Doctors Object to High Cancer-Drug Prices (July 23)




The high cost of prescription drugs

The high cost of prescription drugs

Our Quarterly Newsletter

* indicates required